MGC Diagnostics Corporation Announces Partnership with Frontera Strategies, LP

MGC Diagnostics Corporation Announces Partnership with Frontera Strategies, LP

PR Newswire

SAINT PAUL, Minn., Feb. 27, 2013

SAINT PAUL, Minn., Feb. 27, 2013 /PRNewswire/ --MGC Diagnostics Corporation
(NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology
company, today announced it has entered into a partnership with Frontera
Strategies, LP ("Frontera"), the leading provider of in-office cardiac,
pulmonary, vascular and neurological testing services. As a result of this
partnership, Frontera has agreed to purchase new cardiopulmonary diagnostic
equipment with customized systems developed and designed by MGC Diagnostics to
better meet the demanding requirements of Frontera's mobile testing
procedures. Based in Irving, Texas, Frontera Strategies has been recognized by
Modern Healthcare as one of the "Best Places to Work" in the healthcare
industry.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

MGC Diagnostics, ranked 'Best-In-Class' by MD Buyline's User Satisfaction
Report^™, is focused on providing non-invasive diagnostic systems with
unmatched service and support throughout the U.S. and internationally.

Kai Pinkerton, Clinical Operations Manager of Frontera, commented "We chose
MGC Diagnostics because of their product quality, service excellence and
attractive company culture. Clinically we were pleased with the products and
MGC Diagnostics was flexible enough to work out a winning solution for us. At
Frontera the experience for our patients and customers is our number one
priority. Partnering with MGC Diagnostics, who leads their industry in service
excellence, was a natural fit."

Richard Baker, Co-founder and Partner of Frontera, added "As a leader in
mobile diagnostic services, we are excited to partner with MGC Diagnostics to
better serve our customers and their patients within the Oklahoma and Texas
markets. Our goal is to be a thought leader in driving down healthcare costs
and we are looking for ways to bring better, more cost efficient diagnostic
testing to the marketplace."

Gregg O. Lehman, Ph.D., Chief Executive Officer and President of MGC
Diagnostics, commented "We are pleased to have been chosen by Frontera to
assist them in maintaining a leadership role in mobile testing. As part of our
efforts to improve patient outcomes and reduce healthcare costs, we remain
committed to providing innovative diagnostic equipment to mobile testing
services focused at physicians' offices, as well as at traditional healthcare
facilities."

About Frontera Strategies
Frontera is the leading provider of in-office cardiac, pulmonary, vascular and
neurological testing services. With more than 2,000 partners across Texas and
Oklahoma, Frontera serves physicians in Dallas, Ft. Worth, Austin, Houston,
San Antonio, Lubbock, Amarillo, Oklahoma City and Tulsa. Frontera was founded
in 2001 by partners Richard Baker, Nate Nelson and Ches Williams. For more
information, please visit: http://www.teamfrontera.com.

About MGC Diagnostics
MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is
a global medical technology company dedicated to cardiorespiratory health
solutions. MGC Diagnostics develops, manufactures and markets non-invasive
diagnostic systems. This portfolio of products provides solutions for disease
detection, integrated care, and wellness across the spectrum of
cardiorespiratory healthcare. The Company's products are sold internationally
through distributors and in the United States through a direct sales force
targeting heart and lung specialists located in hospitals, university-based
medical centers, medical clinics, physicians' offices, pharmaceutical
companies, medical device manufacturers, and clinical research organizations
(CROs). For more information about MGC Diagnostics, visit
www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking Statements
From time to time, in reports filed with the Securities and Exchange
Commission, in press releases, and in other communications to shareholders or
the investing public, MGC Diagnostics Corporation may make forward−looking
statements concerning possible or anticipated future financial performance,
business activities or plans that include the words "believes," "expects,"
"anticipates," "intends" or similar expressions. For these forward−looking
statements, the Company claims the protection of the safe harbor for
forward−looking statements contained in federal securities laws. These
forward−looking statements are subject to a number of factors, risks and
uncertainties, including those disclosed in our periodic filings with the SEC,
that could cause actual performance, activities or plans after the date the
statements are made to differ significantly from those indicated in the
forward−looking statements. For a list of these factors¸ see the sections
entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking
Statements," in the Company's Form 10-K for the year ended October 31, 2012,
and any updates in subsequent filings on Form 10-Q or Form 8-K under the
Securities Exchange Act of 1934.

Contact:  Gregg O. Lehman, Ph.D.       Joe Dorame, Robert Blum, Joe
                                                  Diaz
              MGC Diagnostics Corporation    Lytham Partners, LLC
              Chief Executive                     (602) 889-9700
              Officer
              (651) 484-4874           mgcd@lythampartners.com

SOURCE MGC Diagnostics Corporation

Website: http://www.mgcdiagnostics.com